



NICOLAUS COPERNICUS  
UNIVERSITY  
IN TORUŃ



**Quality in Sport. eISSN 2450-3118.**

**Journal Home Page**

**<https://apcz.umk.pl/QS/index>**

**MATCZAK, Simon, NAMYSŁ, Maria, SOBKOWIAK, Marcin, WOŹNIAK, Kinga, BIENIEK, Maciej, ŻUKOWSKI, Marcel, MODELSKI, Mikołaj, OSADA, Julia, DZIERBICKA, Nikola, and KULPA, Agnieszka. Management of Anterior Cruciate Ligament Rupture: A Narrative Review of Emerging Therapeutic Methods. Quality in Sport. 2026;54:70328. eISSN 2450-3118. <https://doi.org/10.12775/QS.2026.54.70328>**

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).

Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.

Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych). © The Authors 2026. This article is published with open access under the License Open Journal Systems of Nicolaus Copernicus University in Toruń, Poland. Open Access: This article is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non-commercial Share Alike License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interest regarding the publication of this paper.  
Received: 27.03.2026. Revised: 03.04.2026. Accepted: 08.04.2026. Published: 09.04.2026.

---

## **Management of Anterior Cruciate Ligament Rupture: A Narrative Review of Emerging Therapeutic Methods**

**Simon Matczak<sup>1</sup>**

ORCID <https://orcid.org/0009-0000-9191-6847>

E-mail: [szymon.matczak00@gmail.com](mailto:szymon.matczak00@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-70, Poznan, Poland

**Maria Namysl<sup>2</sup>**

ORCID <https://orcid.org/0009-0009-8682-1718>

E-mail: [missnamysl@gmail.com](mailto:missnamysl@gmail.com)

<sup>2</sup>Poznan Clinical University Hospital, Przybyszewskiego 49, 60-355, Poznan, Poland

**Marcin Sobkowiak<sup>3</sup>**

ORCID <https://orcid.org/0009-0008-3053-5213>

E-mail: [sobkowiakkonin@gmail.com](mailto:sobkowiakkonin@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Kinga Woźniak<sup>4</sup>**

ORCID <https://orcid.org/0009-0008-0218-994X>

E-mail: [kwump85@gmail.com](mailto:kwump85@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Maciej Bieniek<sup>5</sup>**

ORCID <https://orcid.org/0009-0008-2432-1980>

E-mail: [macijbieniek99@gmail.com](mailto:macijbieniek99@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Marcel Żukowski<sup>6</sup>**

ORCID <https://orcid.org/0009-0001-9126-9579>

E-mail: [marcel.artur.zukowski@gmail.com](mailto:marcel.artur.zukowski@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Mikołaj Modelski<sup>7</sup>**

ORCID <https://orcid.org/0009-0004-4724-8342>

E-Mail: [mikolaj.modelski@gmail.com](mailto:mikolaj.modelski@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Julia Osada<sup>8</sup>**

ORCID <https://orcid.org/0009-0008-2330-1929>

E-Mail: [gjwalecko@gmail.com](mailto:gjwalecko@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Nikola Dzierbicka<sup>9</sup>**

ORCID: <https://orcid.org/0009-0001-6499-8346>

E-Mail: [nikola.dzierbicka@gmail.com](mailto:nikola.dzierbicka@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

**Agnieszka Kulpa<sup>10</sup>**

ORCID <https://orcid.org/0009-0001-9287-7832>

E-Mail: [agnieszka.kulpa1@gmail.com](mailto:agnieszka.kulpa1@gmail.com)

<sup>1</sup>Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland

Corresponding author:

Simon Matczak, E-mail: [szymon.matczak00@gmail.com](mailto:szymon.matczak00@gmail.com)

## **ABSTRACT**

**Background.** Anterior cruciate ligament (ACL) rupture is a common orthopedic injury that significantly impacts athletic performance and long-term joint stability. While surgical reconstruction (ACLR) remains the current gold standard, there are concerns regarding graft failure, persistent rotational laxity, and the development of post-traumatic osteoarthritis.

**Aim.** This narrative review aims to analyze emerging therapeutic methods in ACL management, including modern surgical techniques, orthobiologic therapies, and tissue engineering, in terms of their clinical efficacy and limitations regarding their implementation to clinical practice.

**Methodology.** A literature search was conducted using PubMed, Web of Science, and Google Scholar. Meta-analyses, randomized controlled trials, and systematic reviews focusing on innovative therapeutic methods for ACL injuries were included.

**Results.** Primary repair with internal bracing and bridge-enhanced ACL repair technique show promise in joint preservation but are strictly dependent on tear morphology. Extra-articular augmentation have potential to reduce rotational laxity in high-risk cohorts. Platelet-rich plasma and mesenchymal stem cells may promote "ligamentization," though clinical evidence remains inconsistent due to a lack of standardized preparation protocols. Tissue engineering techniques, such as 3D bioprinting and electrospinning offer biomimetic potential, although there are significant regulatory and economic barriers.

**Conclusions.** Emerging therapeutic methods in ACL injury management offer promising advantages when combined with traditional ACLR. However, their widespread implementation

is currently limited by high costs, a lack of long-term clinical data, and the need for standardized application protocols. Future research is needed to determine their the long-term effectiveness of these techniques and and to define their precise role in routine clinical practice.

**Keywords:** Anterior Cruciate Ligament; ACL Reconstruction; Tissue Regeneration; Bridge-Enhanced ACL Repair; ACL injury; Orthobiologics

## INTRODUCTION

Anterior cruciate ligament (ACL) rupture is one of the most common orthopaedic injuries, accounting for approximately 20% of all sport-related injuries of the knee joint. (1) It typically affects young and physically active patients, and usually occurs during physical activities that involve pivoting, jumping, or rapid deceleration, such as football, basketball, and skiing. (2–5) Structurally, the ACL consists of two bundles - anteromedial and posterolateral - which together play a crucial role in stabilizing the knee joint, particularly by limiting excessive forward movement of the tibia and providing resistance to rotational forces. (1–3,5) Rupture of the ACL results in immediate functional instability and compromised athletic performance. It has also been associated with long-term complications such as cartilage damage, meniscus injuries, and an increased risk of osteoarthritis, often leading to premature joint degeneration. (2–4,6,7)

For decades, the "gold standard" for managing these injuries has been surgical ACL reconstruction (ACLR) using autografts or allografts. (5,7) Although this approach has largely proven effective in terms of maintaining knee stability, it comes with several limitations. Firstly, ACLR often fails to restore normal joint kinetics, and may lead to persistent translational and rotational laxity. A significant number of patients treated with ACLR do not return to their pre-injury level of sport, and a substantial number of patients experience graft re-rupture. Secondly, evidence states that ACLR does not significantly reduce the risk of post-traumatic osteoarthritis, suggesting that current methods do not fully prevent biological degeneration of the knee joint. Additionally, the use of autografts is associated with tissue morbidity, while allografts carry the risk of biological integration failure and pathogen transmission. (8–12)

These challenges have started an ongoing debate regarding the optimal first-line treatment - early surgery versus primary rehabilitation. (1–3,5,6,13,14) Operative treatment remains the method of choice in young patients and those wishing to return to high-demanding sports. (15,16) However, the emerging evidence suggests that conservative treatment is also effective in certain individuals and may bring similar patient-reported functional outcomes compared to

surgical intervention. Consequently, the orthopedic community is currently facing a period of uncertainty where neither surgical treatment nor conservative approach can guarantee a return to pre-injury levels of joint integrity for all patients. In response to these challenges, recent clinical guidelines and consensus statements increasingly recommend an individualized decision-making approach. Multiple factors are taken into account when choosing the optimal therapeutic strategy, including the patient's level of physical activity, extent of injury, functional instability, and expectations regarding return to sport. (3,4,7,17)

This also prompted the development of multiple emerging techniques, including innovative surgical solutions aimed at preserving native ACL tissue, or advancements in biological and regenerative medicine to enhance healing of the ligament. (18–20) Moreover, novel strategies for adjunctive stabilization and personalized rehabilitation protocols have been introduced. (21,22) This narrative review aims to analyze the most prominent emerging therapeutic methods in the management of ACL rupture. These will include recent advancements in the following: ACL repair and augmentation techniques, biological and regenerative strategies, adjunctive extra-articular stabilization, and personalized rehabilitation methods.

## **METHODOLOGY**

This report is structured as a narrative review. The literature search was conducted across PubMed, Web of Science, and Google Scholar using the following keywords: “anterior cruciate ligament”, “anterior cruciate ligament AND internal bracing”, “bridge-enhanced ACL repair”, “anterior cruciate ligament AND extra-articular augmentation”, “orthobiologics”, “anterior cruciate ligament AND platelet-rich plasma”, “anterior cruciate ligament AND stem cells”, “anterior cruciate ligament AND scaffolding”, “anterior cruciate ligament AND bioprinting”, “anterior cruciate ligament AND electrospinning”.

The search included meta-analyses, systematic reviews, and randomized controlled trials that examined the emerging treatment approaches in patients with ACL rupture. Exclusion criteria eliminated case reports, studies of low methodological quality, and non-English publications.

## **REVIEW**

### **1. Emerging Surgical Innovations**

#### **1.1 The Resurgence of Primary Repair and Internal Bracing**

The surgical management of ACL ruptures is currently undergoing significant developments with a particular spike in interest concerning joint-preserving techniques. Historically, ACL

repair techniques involving direct suturing of the torn ligament ends were considered the best treatment method and the standard of care as far back as the 1970s and through the 1980s. (19) This approach, however, was largely abandoned due to unacceptably high clinical failure rates observed in follow-up examinations. The primary biological etiology of these failures was the hostile intra-articular environment of the knee joint due to the constant presence of synovial fluid, which contains high levels of the enzyme plasmin responsible for the premature dissolving of the fibrin clot biologically required to bridge the tear gap and initiate natural ligamentous healing. (23) The consequence of these experiences was a gradual shift towards complete tissue resection and mechanical replacement via autograft or allograft reconstruction. (20)

In recent years, modern primary repair has seen a renewed interest, driven largely by a deeper understanding of ligament healing and a more precise selection criteria. (19,20,24) Rather than applying primary repair universally, contemporary orthopedic surgeons rely heavily on the Sherman classification of ACL tears to identify suitable candidates. (19,20) The Sherman classification categorises ACL injuries based on the anatomical location of the rupture and the residual quality of the ligamentous tissue. (8,19)

Current clinical consensus dictates that the primary repair is strictly indicated for Sherman type I tears, proximal avulsions directly at the femoral footprint, or type II tears, provided the remaining ligament exhibits sufficient structural integrity capable of holding tensioned sutures. (5)

To overcome the biomechanical weakness that plagued historical suturing techniques, modern primary repair can now be augmented with a procedure known as internal bracing. This biomechanical concept involves placing a synthetic, ultra-high-molecular-weight polyethylene braided suture tape parallel to the repaired native ligament. The tape is firmly anchored into both the femur and tibia, effectively acting as an internal stabilization for the knee joint. (25–27)

The critical function of this suture tape augmentation is to stress-shield the healing ACL during the vulnerable early phases of healing, by absorbing peak physiological loads and restricting pathological anterior tibial translation during the vulnerable early phases of healing. The internal brace allows patients to undergo early postoperative mobilization and physical therapy without the risk of mechanically stretching or elongating the fragile, repairing tissue. (28–30)

## **1.2 Bridge-Enhanced ACL Repair (BEAR)**

Building upon the biological principles of primary repair, the Bridge-Enhanced ACL Repair (BEAR) technique represents a great leap forward, moving the boundaries of mechanical repair towards tissue engineering. The mechanism of action for the BEAR procedure addresses the fundamental biological flaw of intra-articular ligament healing. The procedure utilizes a proprietary, bioresorbable bovine extracellular matrix (ECM) scaffold sponge that is surgically implanted between the torn ends of the ACL. (31–33) During the surgical intervention, the patient's own autologous whole blood is drawn and injected directly into the highly porous ECM sponge. The scaffold effectively acts as a protective housing, holding the resulting blood clot securely in place against the mechanically and chemically hostile synovial environment. By shielding the clot from plasmin-induced degradation, the BEAR scaffold supports cellular migration and regeneration of the native ligament tissue. (32–35)

The clinical evidence supporting the BEAR technique has been extensively studied. Notably, the BEAR II clinical trial provided landmark data comparing the outcomes of patients treated with the BEAR implant against a control group undergoing traditional autograft ACL reconstruction. At the two-year postoperative mark, the findings demonstrated that the BEAR procedure was statistically non-inferior to standard ACL reconstruction regarding anteroposterior knee laxity measured in objective arthrometric testing, as well as in patient-reported subjective functional outcomes and return-to-sport metrics. (34,36)

The advantages of the BEAR technique over traditional reconstruction align with the goal of minimum interference and joint preservation. Key among them is the preservation of the native tibial and femoral insertion sites. Maintaining these anatomical regions allows for the retention of vital proprioceptive mechanoreceptors and nerve fibers, which are irreversibly severed during graft reconstruction, preserving the patient's innate neuromuscular joint awareness. (37–40) Another advantage is the elimination of the necessity of autograft harvesting. This effectively eliminates all donor-site morbidities associated with ACL surgery, such as chronic knee pain from patellar tendon harvests or enduring flexor weakness from hamstring tendon harvests. (41–43)

## **1.3 Extra-Articular Augmentation**

While primary repair and regenerative techniques address the intra-articular aspect of ACL injuries, emerging surgical innovations have also heavily focused on controlling the extra-articular biomechanics. In 2013, a landmark anatomical dissection study provided a clear qualitative and quantitative description of the anterolateral ligament (ALL), confirming it as a

distinct ligamentous capsule. (44,45) The ALL originates near the lateral epicondyle of the femur and inserts on the proximal tibia, positioned optimally to act as a secondary stabilizer against internal tibial rotation. (44)

The reason for targeting the anterolateral complex stems from the limitations of intra-articular ACL reconstruction. Biomechanical and clinical studies have demonstrated that standard, single-bundle ACL reconstruction alone often underdelivers in stabilizing the knee joint in rotating movements. This residual rotational laxity presents clinically as a persistent “pivot shift” phenomenon, which is correlated with poor subjective knee function, premature cartilage wear, and, eventually, could lead to graft failure. (46–48)

In response, surgeons have experimented with additional extra-articular augmentation techniques, specifically lateral extra-articular tenodesis and formal ALL reconstruction. These procedures are performed concurrently with ACL surgery to mechanically tether the lateral compartment, significantly reducing rotational laxity and offloading rotational forces from the healing intra-articular graft or repair site. (49–51)

It is important to note, however, that extra-articular augmentation is not universally indicated for all ACL ruptures. Major clinical studies, such as the STABILITY study, have established precise criteria identifying target populations who stand to benefit most from lateral extra-articular tenodesis or ALL reconstruction. These high-risk cohorts include patients exhibiting generalized benign joint hypermobility (such as those with elevated Beighton scores), patients undergoing complex revision ACL surgeries due to failure of a previous graft, and particularly young athletes (under 25), who intend to return to dynamic, high-pivoting sports where the rotational demands placed upon the knee are extreme. (52–57)

## **2. Orthobiologics and Regenerative Medicine**

Orthobiologics are a broad range of biological substances used to modulate the inflammatory environment at the injury site and facilitate the healing process. These techniques include, among many, growth factors, stem cells, peripheral blood products, bone marrow-derived products, hyaluronic acid, gene therapy, or synthetic biomaterials. (18,58) In this narrative review, we specifically delve into platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs), which have been selected due to their significant regenerative potential to revolutionize ACL rupture management.

## **2.1 Platelet-Rich Plasma**

PRP is a concentrated suspension of autologous platelets in a small volume of plasma. It is obtained by centrifuging whole blood, which separates its components, allowing for the isolation of a platelet-rich layer. (18) The therapeutic potential of PRP is primarily attributed to the variety of growth factors released upon platelet activation. These include fibroblast growth factor (FGF), transforming growth factor beta (TGF- $\beta$ ), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). These factors are involved in promoting cell differentiation, angiogenesis, tenocyte and fibroblast recruitment, and the synthesis of ECM, thus collectively promoting tissue regeneration. (18,58,59) In the context of ACLR, it is hypothesized that PRP may promote tendon-bone healing by inducing vascularization and structural remodeling of the graft - a process known as "ligamentization". (60,61)

Current research has yielded inconclusive results regarding the efficacy of PRP in ACL injury management. Several meta-analyses and systematic reviews have demonstrated that PRP supplementation enhances early subjective functional scores, with most of the studies describing an improvement approximately 6 months after ACLR. (62–64) A systematic review and meta-analysis by Gan et al. found that the PRP group exhibited significantly higher International Knee Documentation Committee (IKDC) scores at 3, 6, and 12 months postoperatively compared to control groups. Additionally, Lysholm scores improved significantly 3 months after surgery. (62) These findings are partially supported by Zhang et al., who observed statistically significant improvements in subjective outcomes, as measured by IKDC and Lysholm scores, 6 months following ACLR. However, these improvements did not consistently reach clinically significant thresholds. Moreover, by the 12-month follow-up, any perceived functional advantage had diminished further. (61) On the other hand, a meta-analysis by Gang et al. found no improvements in IKDC or Lysholm scores following PRP treatment at any follow-up interval. (65) These findings suggest that the long-term functional impact of PRP in ACL injury remains uncertain.

Regarding pain management, multiple studies report that PRP administration significantly diminishes early postoperative pain levels. However, it does not provide long-term pain reduction. (59,61,62,65)

The impact of PRP on objective knee stability remains the primary point of debate. While a meta-analysis by Serag et al. reports that PRP may bring a significant improvement in postoperative knee stability, as supported by moderate evidence, other studies provide less optimistic conclusions. Zhang et al. reported that objective knee stability showed no statistically significant difference between the PRP and control groups. Furthermore, a meta-analysis by Zhu et al. concluded that while PRP facilitates earlier functional recovery, it does not significantly alter long-term knee function or improve overall graft rupture rates. (59,61,66)

The influence of PRP has also been analyzed in terms of the "ligamentization" of the graft, which is a critical phase of recovery. The results of recent randomized controlled trials by Gong et al. and Munde et al. suggest that intra-articular PRP supplementation may enhance early graft maturity. However, Gong et al. concluded that PRP had no significant effect on reducing bone tunnel widening or accelerating tendon–bone healing. Moreover, a meta-analysis by Zhang et al. reported that there was no statistical difference in tunnel enlargement after PRP administration compared to control groups. Consequently, the current evidence suggests that while PRP may improve graft maturation, its ability to prevent structural complications like tunnel widening remains unsupported. (61,67,68)

The main challenge regarding the widespread use of PRP is the lack of standardization, specifically regarding leukocyte levels and how many injections are needed. (64,69) Until standardized protocols are implemented, PRP should be considered an elective adjunct focused on early-phase recovery in ACL injury patients. (61,62)

## **2.2 Mesenchymal Stem Cells**

MSCs have been extensively studied in recent years for their potential as a supportive treatment in ACL injuries. Recent evidence suggests that they may accelerate tendon-bone healing by enhancing cell proliferation and differentiation, therefore contributing to the formation of fibrocartilage and bone. The primary mechanism of action of MSCs involves the secretion of extracellular vesicles, specifically exosomes, which carry bioactive proteins, lipids, and nucleic acids to target cells at the injury site. Emerging research claims that MSCs-derived exosomes promote angiogenesis and osteogenesis, therefore improving graft reconstruction after ACLR. Moreover, MSCs exhibit endocrine and immunomodulatory properties, aiding the damaged tissues to undergo self-repair. They may secrete anti-inflammatory cytokines and polarize macrophages from a pro-inflammatory (M1 macrophage) to a pro-healing (M2 macrophage)

state. This modulation is crucial as it protects the graft from proteolytic degradation and enhances new bone formation around the tunnel. (60,70,71)

Preclinical studies on animals suggest that MSCs may enhance the structural integrity of the graft-tunnel interface. Histological examinations demonstrate that groups treated with MSCs exhibited significantly higher bone volume fractions compared to control groups. Specifically, greater cellularity, increased collagen deposition, and enhanced vascularization within the graft were observed in the MSCs groups. (72,73)

While preclinical data show promising results, their translation to clinical practice remains a challenge. Although an exploratory study by Moon et al. confirmed the safety of MSCs administration during ACLR, their authors questioned the functional superiority of MSCs use. In this study, the patients receiving human umbilical cord blood-derived MSCs showed no significant difference in objective knee stability or subjective functional scores at a 24-month follow-up when compared to standard ACLR groups. (74,75) However, promising results have been obtained in clinical trials regarding a combined therapy of MSCs + PRP. For instance, a randomized, double-blinded study by Lin et al. demonstrated that the intra-operative application of bone marrow aspiration concentrate in combination with PRP significantly improved objective knee stability. Specifically, a reduction in side-to-side laxity was observed. However, the subjective functional scores, including IKDC and Lysholm scale, did not significantly differ from the control group in the short-term follow-up period. (76)

This highlights the need to optimize protocols for MSCs to ensure that the observed biological enhancements in graft quality and joint stability translate into beneficial long-term clinical outcomes. (60,74)

### **3. Tissue Engineering and Biomaterials**

The primary challenge in the move towards less invasive scaffold-based biological regeneration could be described as a sort of paradox. On one hand, the material used must be strong enough to withstand immediate postoperative mobilization while being porous and bioactive enough to allow for cellular infiltration and deposition of the ECM in the healing tissue, as well as tissue remodeling. (77–79)

### **3.1 Material types: Natural vs. Synthetic**

In the hierarchy of biomaterials, scientists categorize scaffolds into natural and synthetic polymers, each presenting distinct trade-offs in degradation and strength. Natural polymers, specifically Type I collagen and Silk Fibroin, are frequently cited for their excellent biocompatibility. Collagen, as the primary structural protein of the native ACL, provides intrinsic advantages such as easier cell attachment. However, high-quality studies indicate that pure collagen scaffolds lack the mechanical durability required for proper stabilisation of the knee joint, frequently exhibiting enzymatic degradation that outpaces the rate of new tissue formation. Silk Fibroin has emerged as a robust natural alternative as it is characterised by superior tensile strength and a slower, more predictable degradation rate. (80–82)

Conversely, synthetic polymers like polycaprolactone (PCL) and polylactic acid offer high-fidelity control over mechanical properties. PCL is favored for its slow degradation (often over 24 months), which provides a stable scaffold for long-term healing. However, synthetics are inherently hydrophobic, which can lead to poor cell seeding efficiency and potential for “stress shielding” - a situation where the scaffold carries too much load, preventing the developing tissue from strengthening. Current trends in medical literature point toward composite scaffolds - using a PCL core for strength and a collagen coating for its bioactive potential as the most effective strategy for balancing these competing needs. (83–86)

### **3.2 Electrospinning: Mimicking Native Structure**

The native ACL is a highly organised tissue characterised by anisotropic alignment, meaning its collagen fibers are oriented in a specific direction to resist the tensile forces of knee rotation and translation. Electrospinning is the premier manufacturing technique to replicate this structure. By applying a high voltage charge to a polymer solution, ultrafine nanofibers are ejected toward a collector. When combined with a high-speed rotational force in the collector, the fibers are deposited in a parallel, longitudinal orientation rather than a mat of randomly interwoven fibers. Research confirms that this directional alignment is vital for “contact guidance”. When Mesenchymal Stem Cells or ACL fibroblasts are seeded onto these aligned fibers, they physically elongate and align themselves along the fiber axis. (87,88) This alignment triggers the expression of scleraxis and tenomodulin, essential for ligament-specific differentiation. Without this directional topography, cells tend to adopt a disorganised, myofibroblastic phenotype, leading to a decrease in strength to linear forces during exercise. (87,89)

### **3.3 Bioprinting and the Tri-phasic Interface**

While electrospinning excels at creating the mid-substance of the ligament, it struggles to replicate the complex enthesis (the connection between the bone and the ligament). This is where 3D bioprinting can lead to a revolution in this area. The concept is based on creating patient-specific constructs by translating MRI and CT DICOM data into a blueprint. This allows for the fabrication of a graft that fits the patient's unique femoral and tibial tunnel dimensions, reducing the risk of graft mismatch, which is a leading cause of early ACL revision surgeries. (90–92)

The most significant advancement in this sector is the development of Tri-phasic Constructs. In nature, the ACL does not insert into the bone abruptly; the connection transitions through four distinct zones: ligament, non-mineralised fibrocartilage, mineralised fibrocartilage, and finally bone. Recreating this connection is exceedingly difficult, but it has the potential to limit the chances of stress shielding and graft pull-out. Bioprinting enables a gradient approach, depositing different cell-laden materials in a sequential matter, with the goal of mimicking the natural structure. (93,94)

Clinical research suggests that these bioprinted gradients could significantly improve the distribution of mechanical strain. (95,96) In traditional ACL reconstruction using autografts, the connection is the weakest link; bioprinted scaffolds allow for a biological 'interlocking' where the bone grows into the scaffolds while the middle becomes a flexible, fibrous cord. Furthermore, the use of materials such as Pluronic F-127 during the process allows for the creation of micro-channels within the scaffolds, which facilitates angiogenesis, addressing the problem of core necrosis in thick tissue-engineered constructs. (97–100) By integrating MRI-based precision with multi-material gradient printing, bioprinting offers a pathway toward a 'living' ACL replacement that can remodel and grow with the patient, a feat that is impossible with synthetic and highly limited with autografts. (101,102)

### **4. Challenges and Future Directions**

Despite substantial progress in the development of novel strategies for managing ACL injuries, they are inevitably linked with certain limitations. Firstly, extensive safety and efficacy data is required for each of these methods in order for them to be approved and implemented into widespread clinical practice. Secondly, the costs of development and widespread implementation of these techniques are high. As a result, access to these innovations may

initially be limited to specialized centers, elite athletes, or patients with greater financial resources. (103) Finally, the field faces a significant challenge related to the standardization of biologic therapies, particularly PRP and MSCs treatments. Current clinical studies use widely varying preparation techniques, platelet concentrations, and injection protocols, making it difficult to compare results across trials. (104) Establishing standardized preparation methods and reporting guidelines will be essential for generating high-quality evidence and determining the true clinical value of these therapies.

## **CONCLUSIONS**

Emerging surgical, biomechanical and regenerative strategies show promising potential as adjuncts to standard treatment in ACL rupture management. However, their clinical application remains limited by variability in protocols, high costs, and a lack of long-term evidence. Further high-quality, standardized studies are required to determine their effectiveness and optimal use of these methods in day-to-day practice.

## **DISCLOSURES**

### **Authors' contribution:**

Conceptualization: Simon Matczak, Maria Namysł

Methodology: Mikołaj Modelski, Julia Osada

Software: not applicable.

Check: Marcel Żukowski, Kinga Woźniak

Formal analysis: Maciej Bieniek, Marcel Żukowski

Investigation: Maria Namysł, Marcin Sobkowiak

Resources: Nikola Dzierbicka, Agnieszka Kulpa

Data curation: Kinga Woźniak, Maciej Bieniek

Writing - rough preparation: Simon Matczak, Maria Namysł, Marcin Sobkowiak

Writing - review and editing: Mikołaj Modelski, Julia Osada, Nikola Dzierbicka

Visualization: Agnieszka Kulpa

Supervision: Simon Matczak

Project administration: Simon Matczak

All authors have read and agreed with the published version of the manuscript.

**Funding Statement:** The study did not receive special funding.

**Institutional Review Board Statement:** Not Applicable.

**Informed Consent Statement:** Not Applicable.

**Data Availability Statement:** Not Applicable.

**Conflict of Interest:** The authors declare no conflict of interest.

During the preparation of this work, the authors used Google's Chat Generative Pre-trained Transformer (Google AI Studio) to support the editing process, including grammar, spelling, punctuation, and stylistic refinement. All content generated with AI assistance was carefully reviewed and revised by the authors, who accept full responsibility for the accuracy, interpretation, and integrity of the final manuscript.

## REFERENCES

1. Lam MH, Fong DT, Yung PS, Ho EP, Chan WY, Chan KM. Knee stability assessment on anterior cruciate ligament injury: Clinical and biomechanical approaches. *BMC Sports Sci Med Rehabil.* 2009 Dec;1(1):20. doi:10.1186/1758-2555-1-20
2. Satora W, Królikowska A, Czamara A, Reichert P. Synthetic grafts in the treatment of ruptured anterior cruciate ligament of the knee joint. *Polym Med.* 2017 Oct 2;47(1):55–9. doi:10.17219/pim/76819
3. Papaleontiou A, Poupard AM, Mahajan UD, Tsantanis P. Conservative vs Surgical Treatment of Anterior Cruciate Ligament Rupture: A Systematic Review. *Cureus.* 2024 Mar;16(3):e56532. doi:10.7759/cureus.56532 PubMed PMID: 38646275; PubMed Central PMCID: PMC11027445.
4. Jia Z, Greven J, Hildebrand F, Kobbe P, Eschweiler J. Conservative treatment versus surgical reconstruction for ACL rupture: A systemic review. *J Orthop.* 2024 Nov;57:8–16. doi:10.1016/j.jor.2024.05.026 PubMed PMID: 38948499; PubMed Central PMCID: PMC11208802.
5. The Panther Symposium ACL Treatment Consensus Group, Diermeier T, Rothrauff BB, Engbretsen L, Lynch AD, Ayeni OR, et al. Treatment after anterior cruciate ligament injury: Panther Symposium ACL Treatment Consensus Group. *Knee Surg Sports Traumatol Arthrosc.* 2020 Aug;28(8):2390–402. doi:10.1007/s00167-020-06012-6
6. Saueressig T, Braun T, Steglich N, Diemer F, Zebisch J, Herbst M, et al. Primary surgery versus primary rehabilitation for treating anterior cruciate ligament injuries: a living

- systematic review and meta-analysis. *Br J Sports Med.* 2022 Nov;56(21):1241–51. doi:10.1136/bjsports-2021-105359 PubMed PMID: 36038357; PubMed Central PMCID: PMC9606531.
7. Brophy RH, Lowry KJ. American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary: Management of Anterior Cruciate Ligament Injuries. *J Am Acad Orthop Surg.* 2023 Jun 1;31(11):531–7. doi:10.5435/JAAOS-D-22-01020
  8. Kiapour AM, Murray MM. Basic science of anterior cruciate ligament injury and repair. *Bone Jt Res.* 2014 Feb;3(2):20–31. doi:10.1302/2046-3758.32.2000241
  9. De Jonge R, Máté M, Kovács N, Imrei M, Pap K, Agócs G, et al. Nonoperative Treatment as an Option for Isolated Anterior Cruciate Ligament Injury: A Systematic Review and Meta-analysis. *Orthop J Sports Med.* 2024 Apr;12(4):23259671241239665. doi:10.1177/23259671241239665
  10. Cuzzolin M, Previtali D, Zaffagnini S, Deabate L, Candrian C, Filardo G. Anterior Cruciate Ligament Reconstruction versus Nonoperative Treatment: Better Function and Less Secondary Meniscectomies But No Difference in Knee Osteoarthritis—A Meta-Analysis. *CARTILAGE.* 2021 Dec;13(1\_suppl):1658S-1670S. doi:10.1177/19476035211046041
  11. Wiggins AJ, Grandhi RK, Schneider DK, Stanfield D, Webster KE, Myer GD. Risk of Secondary Injury in Younger Athletes After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis. *Am J Sports Med.* 2016 Jul;44(7):1861–76. doi:10.1177/0363546515621554
  12. Manara JR, Salmon LJ, Kilani FM, Zelaya De Camino G, Monk C, Sundaraj K, et al. Repeat Anterior Cruciate Ligament Injury and Return to Sport in Australian Soccer Players After Anterior Cruciate Ligament Reconstruction With Hamstring Tendon Autograft. *Am J Sports Med.* 2022 Nov;50(13):3533–43. doi:10.1177/03635465221125467
  13. Jia C, Liu X, Ning L, Ge L. The Effects of Augmented Reality on Rehabilitation of Stroke Patients: A Systematic Review and Meta-Analysis With Trial Sequential Analysis. *J Clin Nurs.* 2025 Nov;34(11):4578–89. doi:10.1111/jocn.17730
  14. Van Yperen DT, Reijman M, Van Es EM, Bierma-Zeinstra SMA, Meuffels DE. Twenty-Year Follow-up Study Comparing Operative Versus Nonoperative Treatment of Anterior Cruciate Ligament Ruptures in High-Level Athletes. *Am J Sports Med.* 2018 Apr;46(5):1129–36. doi:10.1177/0363546517751683

15. Musahl V, Diermeier T, De Sa D, Karlsson J. “ACL surgery: when to do it?” *Knee Surg Sports Traumatol Arthrosc.* 2020 Jul;28(7):2023–6. doi:10.1007/s00167-020-06117-y
16. Hada S, Hada M, Yoshida K, Kaneko H, Saita Y, Kubota M, et al. Conservative treatment using platelet-rich plasma for acute anterior cruciate ligament injuries in highly active patients [Internet]. 2024 [cited 2026 Mar 8]. Available from: <https://www.researchsquare.com/article/rs-3833973/v1> doi:10.21203/rs.3.rs-3833973/v1
17. Tigerstrand Grevnerts H. Treatment Decision after Anterior Cruciate Ligament Injury, and Evaluation of Measurement Properties of a Patient Reported Outcome Measure [Internet]. Vol. 1706. Linköping: Linköping University Electronic Press; 2019 [cited 2026 Mar 8]. (Linköping University Medical Dissertations). Available from: <https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-160918> doi:10.3384/diss.diva-160918
18. Yu X, Hu J, Li Y, Wen Y, Li B. ACL injury management: a comprehensive review of novel biotherapeutics. *Front Bioeng Biotechnol.* 2024 Nov 22;12:1455225. doi:10.3389/fbioe.2024.1455225
19. Mahapatra P, Horriat S, Anand BS. Anterior cruciate ligament repair – past, present and future. *J Exp Orthop.* 2018 Jan;5(1):20. doi:10.1186/s40634-018-0136-6
20. Malahias MA, Chytas D, Nakamura K, Raoulis V, Yokota M, Nikolaou VS. A Narrative Review of Four Different New Techniques in Primary Anterior Cruciate Ligament Repair: “Back to the Future” or Another Trend? *Sports Med - Open.* 2018 Dec;4(1):37. doi:10.1186/s40798-018-0145-0
21. Homan MD, Braaten JA, Banovetz MT, Monson JK, Kennedy NI, LaPrade RF. Principles for optimizing anterior cruciate ligament reconstruction outcomes in elite athletes: a review of current techniques. *Ann Jt.* 2024 Apr;9:19–19. doi:10.21037/aoj-22-40
22. Filbay SR, Dowsett M, Chaker Jomaa M, Rooney J, Sabharwal R, Lucas P, et al. Healing of acute anterior cruciate ligament rupture on MRI and outcomes following non-surgical management with the Cross Bracing Protocol. *Br J Sports Med.* 2023 Dec;57(23):1490–7. doi:10.1136/bjsports-2023-106931
23. Andersen RB, Gormsen J. Fibrin dissolution in synovial fluid. *Acta Rheumatol Scand.* 1970;16(4):319–33. PubMed PMID: 4099587.
24. Migliorini F, Vecchio G, Eschweiler J, Schneider SM, Hildebrand F, Maffulli N. Reduced knee laxity and failure rate following anterior cruciate ligament reconstruction compared with repair for acute tears: a meta-analysis. *J Orthop Traumatol.* 2023 Feb 20;24(1):8. doi:10.1186/s10195-023-00688-5

25. Ostrander R, Jordan S, Konicek J, Baldwin W. Suture Tape–Augmented Posterior Cruciate Ligament Repair Should Be Tensioned and Fixed at Approximately 100° Knee Flexion to Prevent Loss of Full Flexion. *Arthrosc Sports Med Rehabil*. 2021 Dec;3(6):e1811–8. doi:10.1016/j.asmr.2021.08.008
26. Zheng T, Cao Y, Song G, Li Y, Zhang Z, Feng Z, et al. Suture tape augmentation, a novel application of synthetic materials in anterior cruciate ligament reconstruction: A systematic review. *Front Bioeng Biotechnol*. 2023 Jan 3;10:1065314. doi:10.3389/fbioe.2022.1065314
27. Torres SJ, Nelson TJ, Pham N, Uffmann W, Limpisvasti O, Metzger MF. Suture Tape Augmentation Increases the Time-Zero Stiffness and Strength of Anterior Cruciate Ligament Grafts: A Cadaveric Study. *Arthrosc Sports Med Rehabil*. 2022 Aug;4(4):e1253–9. doi:10.1016/j.asmr.2022.02.008
28. Irfan A, Kerr S, Hopper G, Wilson W, Wilson L, Mackay G. A Criterion Based Rehabilitation Protocol for ACL Repair with Internal Brace Augmentation. *Int J Sports Phys Ther*. 2021 Jun 1;16(3). doi:10.26603/001c.22217
29. Hušek F, Mizera R, Čapek L, Horák Z. Early Surgical Treatment Options for Anterior Cruciate Ligament Injury. *Acta Chir Orthop Traumatol Cech*. 2025 Mar 13;92(1):45–51. doi:10.55095/achot2024/055
30. Handzewniak N, Pearse R, Randall A, Mahmood A, Khan T, Khan S, et al. Augmented Tendon Repair with Internal Bracing: Surgical Technique. *J Clin Med*. 2025 Nov 10;14(22):7963. doi:10.3390/jcm14227963
31. BEAR-MOON Design Group, Spindler KP, Imrey PB, Yalcin S, Beck GJ, Calbrese G, et al. Design Features and Rationale of the BEAR-MOON (Bridge-Enhanced ACL Restoration Multicenter Orthopaedic Outcomes Network) Randomized Clinical Trial. *Orthop J Sports Med*. 2022 Jan 1;10(1):23259671211065447. doi:10.1177/23259671211065447
32. Shah AK, Neijna AG, Retzky JS, Gomoll AH, Strickland SM. Indications, Techniques, and Outcomes of Bridge-Enhanced ACL Restoration (BEAR). *Curr Rev Musculoskelet Med*. 2025 Feb 12;18(4):140–8. doi:10.1007/s12178-025-09950-1
33. McMillan S, Sigman S, Dougherty C, Ford E. “About The Innovation™...Bridge Enhanced ACL Restoration (BEAR): Why, How, and When.” *J Orthop Exp Innov*. 2022 Sep 20;3(2). doi:10.60118/001c.38392
34. Murray MM, Kalish LA, Fleming BC, BEAR Trial Team, Flutie B, Freiburger C, et al. Bridge-Enhanced Anterior Cruciate Ligament Repair: Two-Year Results of a First-in-

- Human Study. *Orthop J Sports Med.* 2019 Mar 1;7(3):2325967118824356. doi:10.1177/2325967118824356
35. McMillan S, Putra J, Patel S, Kramer DE, Anthony S, Ford EA, et al. Histological Analysis of Bridge-Enhanced ACL Restoration (BEAR) Tissue in Ligament Retears. *Orthop J Sports Med.* 2025 Apr;13(4):23259671251331046. doi:10.1177/23259671251331046
  36. Shah KP, Gelatt T, Damaraju K, Elias J, Shah S, Ford E, et al. Bridge Enhanced ACL Repair (BEAR) versus Bone Patella Tendon Bone (BPTB) ACL reconstruction among young athletes: A systematic review and meta-analysis. *J Orthop.* 2026 Mar;73:30–41. doi:10.1016/j.jor.2025.12.008
  37. Wang HD, Wang FS, Gao SJ, Zhang YZ. Remnant preservation technique versus standard technique for anterior cruciate ligament reconstruction: a meta-analysis of randomized controlled trials. *J Orthop Surg.* 2018 Dec;13(1):231. doi:10.1186/s13018-018-0937-4
  38. Ochi M, Abouheif MM, Kongcharoensombat W, Nakamae A, Adachi N, Deie M. Double bundle arthroscopic Anterior Cruciate Ligament reconstruction with remnant preserving technique using a hamstring autograft. *Sports Med Arthrosc Rehabil Ther Technol.* 2011 Dec;3(1):30. doi:10.1186/1758-2555-3-30
  39. Nyland J, Gamble C, Franklin T, Caborn DNM. Permanent knee sensorimotor system changes following ACL injury and surgery. *Knee Surg Sports Traumatol Arthrosc.* 2017 May;25(5):1461–74. doi:10.1007/s00167-017-4432-y
  40. G A. Anterior Cruciate Ligament Mechanoreceptors Regeneration Following Reconstruction Using Autografts. *J Sports Med Doping Stud.* 2013;03(02). doi:10.4172/2161-0673.100e136
  41. Dhammi IK, Rehan-Ul-Haq, Kumar S. Graft choices for anterior cruciate ligament reconstruction. *Indian J Orthop.* 2015 Apr;49(2):127–8. doi:10.4103/0019-5413.152393
  42. Mascarenhas R, MacDonald PB. Anterior cruciate ligament reconstruction: a look at prosthetics - past, present and possible future. *McGill J Med.* 2020 Dec 1;11(1). doi:10.26443/mjm.v11i1.409
  43. Li X, Cao W, Zhou H, Ji R, Xiao J, Zhao C. The healing effect of the all inside technique is superior to the traditional technique in the reconstruction of the anterior cruciate ligament. *Eur J Transl Myol.* 2024 Feb 12. doi:10.4081/ejtm.2024.11970

44. Feucht MJ, Zens M, Frosch KH, Akoto R, Südkamp NP, Niemeyer P. The anterolateral ligament of the knee: anatomy, biomechanics, and clinical implications. *Curr Orthop Pract.* 2016 May;27(3):247–53. doi:10.1097/BCO.0000000000000355
45. Claes S, Vereecke E, Maes M, Victor J, Verdonk P, Bellemans J. Anatomy of the anterolateral ligament of the knee. *J Anat.* 2013 Oct;223(4):321–8. doi:10.1111/joa.12087
46. Wood R, Marsh J, Getgood A. Anterolateral Complex Reconstruction: Another Fad or Method to Improve ACL Outcomes? *Tech Orthop.* 2018 Dec;33(4):239–45. doi:10.1097/BTO.0000000000000310
47. Stability Group, Getgood A, Bryant D, Firth A. The Stability study: a protocol for a multicenter randomized clinical trial comparing anterior cruciate ligament reconstruction with and without Lateral Extra-articular Tenodesis in individuals who are at high risk of graft failure. *BMC Musculoskelet Disord.* 2019 Dec;20(1):216. doi:10.1186/s12891-019-2589-x
48. Ayeni OR, Chahal M, Tran MN, Sprague S. Pivot shift as an outcome measure for ACL reconstruction: a systematic review. *Knee Surg Sports Traumatol Arthrosc.* 2012 Apr;20(4):767–77. doi:10.1007/s00167-011-1860-y
49. Nyland J, Moatshe G, Martin R. Combined ACL and anterolateral ligament reconstruction: time to pivot and shift the focus? *Knee Surg Sports Traumatol Arthrosc.* 2023 Feb;31(2):373–5. doi:10.1007/s00167-022-07072-6
50. Bernholt DL, Kennedy MI, Crawford MD, DePhillipo NN, LaPrade RF. Combined Anterior Cruciate Ligament Reconstruction and Lateral Extra-Articular Tenodesis. *Arthrosc Tech.* 2019 Aug;8(8):e855–9. doi:10.1016/j.eats.2019.03.027
51. Batty L, Lording T. Clinical Results of Lateral Extra-Articular Tenodesis. *Tech Orthop.* 2018 Dec;33(4):232–8. doi:10.1097/BTO.0000000000000309
52. Zsidai B, Piussi R, Thomeé R, Sundemo D, Musahl V, Samuelsson K, et al. Generalised joint hypermobility leads to increased odds of sustaining a second ACL injury within 12 months of return to sport after ACL reconstruction. *Br J Sports Med.* 2023 Aug;57(15):972–9. doi:10.1136/bjsports-2022-106183
53. Sundemo D, Jacobsson MS, Karlsson J, Samuelsson K, Beischer S, Thomeé R, et al. Generalized joint hypermobility does not influence 1-year patient satisfaction or functional outcome after ACL reconstruction. *Knee Surg Sports Traumatol Arthrosc.* 2022 Dec;30(12):4173–80. doi:10.1007/s00167-022-07008-0

54. Sheean AJ, Shin J, Patel NK, Lian J, Guenther D, Musahl V. The Anterolateral Ligament is Not the Whole Story: Reconsidering the Form and Function of the Anterolateral Knee and its Contribution to Rotatory Knee Instability. *Tech Orthop*. 2018 Dec;33(4):219–24. doi:10.1097/BTO.0000000000000303
55. Lindskog J, Piussi R, Simonson R, Högberg J, Samuelsson K, Thomeé R, et al. Lower rates of return to sport in patients with generalised joint hypermobility two years after ACL reconstruction: a prospective cohort study [Internet]. In Review; 2023 [cited 2026 Mar 14]. Available from: <https://www.researchsquare.com/article/rs-2606960/v1> doi:10.21203/rs.3.rs-2606960/v1
56. Larson CM, Bedi A, Dietrich ME, Swaringen JC, Wulf CA, Rowley DM, et al. Generalized Hypermobility, Knee Hyperextension, and Outcomes After Anterior Cruciate Ligament Reconstruction: Prospective, Case-Control Study With Mean 6 Years Follow-up. *Arthrosc J Arthrosc Relat Surg*. 2017 Oct;33(10):1852–8. doi:10.1016/j.arthro.2017.04.012
57. Cristiani R, Engström B, Edman G, Forssblad M, Stålmán A. Revision anterior cruciate ligament reconstruction restores knee laxity but shows inferior functional knee outcome compared with primary reconstruction. *Knee Surg Sports Traumatol Arthrosc*. 2019 Jan 30;27(1):137–45. doi:10.1007/s00167-018-5059-3
58. Costa FR, Pires L, Martins RA, Santos M, Santos GS, Lana JV, et al. Orthobiologics Revisited: A Concise Perspective on Regenerative Orthopedics. *Curr Issues Mol Biol*. 2025 Apr 2;47(4):247. doi:10.3390/cimb47040247 PubMed PMID: 40699646; PubMed Central PMCID: PMC12025442.
59. Zhu T, Zhou J, Hwang J, Xu X. Effects of Platelet-Rich Plasma on Clinical Outcomes After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis. *Orthop J Sports Med*. 2022 Jan;10(1):23259671211061535. doi:10.1177/23259671211061535 PubMed PMID: 35127959; PubMed Central PMCID: PMC8811441.
60. Tian B, Zhang M, Kang X. Strategies to promote tendon-bone healing after anterior cruciate ligament reconstruction: Present and future. *Front Bioeng Biotechnol*. 2023 Mar 13;11:1104214. doi:10.3389/fbioe.2023.1104214
61. Zhang Y, Xiao Z, Fan Z, Zhang Y, Xu J, Wang K. The impact of platelet-rich plasma injection on anterior cruciate ligament reconstruction: a systematic review and meta-analysis. *Front Bioeng Biotechnol*. 2025 Oct 1;13:1625271. doi:10.3389/fbioe.2025.1625271

62. Gan W, Xu Z, Wu C, He J. Effectiveness of platelet-rich plasma in the treatment of anterior cruciate ligament injuries: A Systematic Review and Meta-analysis [Internet]. 2021 [cited 2026 Mar 14]. Available from: <https://www.researchsquare.com/article/rs-1074595/v1> doi:10.21203/rs.3.rs-1074595/v1
63. Lv ZT, Zhang JM, Pang ZY, Wang Z, Huang JM, Zhu WT. The efficacy of platelet rich plasma on anterior cruciate ligament reconstruction: a systematic review and meta-analysis. *Platelets*. 2022 Feb 17;33(2):229–41. doi:10.1080/09537104.2021.1902969
64. Cao Y, Wan Y. Effectiveness of PLATELET-RICH Plasma in Anterior Cruciate Ligament Reconstruction: A Systematic Review of Randomized Controlled Trials. *Orthop Surg*. 2022 Oct;14(10):2406–17. doi:10.1111/os.13279
65. Li G, Deng P, Xiang S, Qiao J, Zhang Y. The effect of platelet-rich plasma on clinical outcomes within two years after anterior cruciate ligament reconstruction: a systematic review and meta-analysis of randomized controlled trials. *J Orthop Surg*. 2025 Nov 21;20(1):1019. doi:10.1186/s13018-025-06308-8
66. Serag I, Abouzid M, Hikal H, Abdelhadi A, Abdelaal MN, Mohamed AG, et al. Platelet-rich plasma in anterior cruciate ligament reconstruction: An updated systematic review and quantitative meta-analysis of randomized controlled trials. *Chin J Traumatol*. 2025 Jul;S1008127525000860. doi:10.1016/j.cjtee.2025.02.008
67. Gong H, Huang B, Zheng Z, Fu L, Chen L. Clinical Use of Platelet-Rich Plasma to Promote Tendon–Bone Healing and Graft Maturation in Anterior Cruciate Ligament Reconstruction—A Randomized Controlled Study. *Indian J Orthop*. 2022 May;56(5):805–11. doi:10.1007/s43465-021-00533-z
68. Munde K, Banerjee S, Gahlot N, Elhence A, Mandal S, Yadav T. Effect of Platelet-Rich Plasma on Healing of Autologous Graft After Anterior Cruciate Ligament Reconstruction: a Randomized Control Trial. *Regen Med*. 2023 Aug;18(8):601–10. doi:10.2217/rme-2023-0108
69. Kunze KN, Pakanati JJ, Vadhera AS, Polce EM, Williams BT, Parvaresh KC, et al. The Efficacy of Platelet-Rich Plasma for Ligament Injuries: A Systematic Review of Basic Science Literature With Protocol Quality Assessment. *Orthop J Sports Med*. 2022 Feb;10(2):23259671211066504. doi:10.1177/23259671211066504 PubMed PMID: 35155701; PubMed Central PMCID: PMC8832618.
70. Xu Y, Zhang WX, Wang LN, Ming YQ, Li YL, Ni GX. Stem cell therapies in tendon-bone healing. *World J Stem Cells*. 2021 Jul 26;13(7):753–75. doi:10.4252/wjsc.v13.i7.753

71. Zhang T, Yan S, Song Y, Chen C, Xu D, Lu B, et al. Exosomes secreted by hypoxia-stimulated bone-marrow mesenchymal stem cells promote grafted tendon-bone tunnel healing in rat anterior cruciate ligament reconstruction model. *J Orthop Transl.* 2022 Sep;36:152–63. doi:10.1016/j.jot.2022.08.001
72. Santoso ARB, Mustamsir E, Luqman Fadli M, Yuarno Phatama K, Wijaya AEP, Dhakka Siahaan L, et al. The Effects of Stromal Vascular Fraction Administration in Stimulating Graft Healing Process after Anterior Cruciate Ligament Reconstruction Surgery in *Rattus norvegicus*. *Open Access Maced J Med Sci.* 2021 Nov 8;9(A):941–5. doi:10.3889/oamjms.2021.7229
73. Zheng H, Zeng Y, Daoerji N, Wang H, Tang B, Shu L. BMP-2 gene-modified mesenchymal stem cells enhance tendon–bone healing in ACL reconstruction: a rabbit micro-CT and biomechanical study. *BMC Surg.* 2025 Nov 5;25(1):526. doi:10.1186/s12893-025-03277-x
74. Moon SW, Park S, Oh M, Wang JH. Outcomes of human umbilical cord blood-derived mesenchymal stem cells in enhancing tendon-graft healing in anterior cruciate ligament reconstruction: an exploratory study. *Knee Surg Relat Res.* 2021 Dec;33(1):32. doi:10.1186/s43019-021-00104-4
75. Dudek S, Koziak W, Makiela M, Bętkowska A, Kornacka A, Dudek W, et al. Reconstruction of the Anterior Cruciate Ligament in Athletes – A Review of Methods and Treatment Outcomes. *Qual Sport.* 2025 Mar 21;39:59286. doi:10.12775/QS.2025.39.59286
76. Lin YC, Chen YJ, Fan TY, Chou PH, Lu CC. Effect of bone marrow aspiration concentrate and platelet-rich plasma combination in anterior cruciate ligament reconstruction: a randomized, prospective, double-blinded study. *J Orthop Surg.* 2024 Jan 3;19(1):4. doi:10.1186/s13018-023-04512-y PubMed PMID: 38169406; PubMed Central PMCID: PMC10763110.
77. Wähnert D, Greiner J, Brianza S, Kaltschmidt C, Vordemvenne T, Kaltschmidt B. Strategies to Improve Bone Healing: Innovative Surgical Implants Meet Nano-/Micro-Topography of Bone Scaffolds. *Biomedicines.* 2021 Jun 28;9(7):746. doi:10.3390/biomedicines9070746
78. Kiselevskiy MV, Anisimova NYu, Kapustin AV, Ryzhkin AA, Kuznetsova DN, Polyakova VV, et al. Development of Bioactive Scaffolds for Orthopedic Applications by Designing Additively Manufactured Titanium Porous Structures: A Critical Review. *Biomimetics.* 2023 Nov 13;8(7):546. doi:10.3390/biomimetics8070546

79. Feldman D. Quantification and Modeling of Biological Processes for Tissue Engineering and Regenerative Medicine. *Biomed J Sci Tech Res*. 2019 Jan 9;12(5). doi:10.26717/BJSTR.2019.12.002329
80. Sun W, Gregory DA, Tomeh MA, Zhao X. Silk Fibroin as a Functional Biomaterial for Tissue Engineering. *Int J Mol Sci*. 2021 Feb 2;22(3):1499. doi:10.3390/ijms22031499
81. Ribeiro VP, Costa JB, Carneiro SM, Pina S, Veloso ACA, Reis RL, et al. Bioinspired Silk Fibroin-Based Composite Grafts as Bone Tunnel Fillers for Anterior Cruciate Ligament Reconstruction. *Pharmaceutics*. 2022 Mar 24;14(4):697. doi:10.3390/pharmaceutics14040697
82. Naghashzargar E, Farè S, Catto V, Bertoldi S, Semnani D, Karbasi S, et al. Nano/Micro Hybrid Scaffold of PCL or P3HB Nanofibers Combined with Silk Fibroin for Tendon and Ligament Tissue Engineering. *J Appl Biomater Funct Mater*. 2015 Jul;13(2):156–68. doi:10.5301/jabfm.5000216
83. Nguyen DM, Murawski CD, Fu FH, Kaufmann RA. Stress Shielding of Ligaments Using Nonabsorbable Suture Augmentation May Influence the Biology of Ligament Healing. *J Hand Surg*. 2022 Mar;47(3):275–8. doi:10.1016/j.jhsa.2021.09.014
84. She Y, Fan Z, Wang L, Li Y, Sun W, Tang H, et al. 3D Printed Biomimetic PCL Scaffold as Framework Interspersed With Collagen for Long Segment Tracheal Replacement. *Front Cell Dev Biol*. 2021 Jan 21;9:629796. doi:10.3389/fcell.2021.629796
85. Baker C, Kirby JB, O'Connor J, Lindsay KG, Hutchins A, Harris M. The Perceived Impact of Ashwagandha on Stress, Sleep Quality, Energy, and Mental Clarity for College Students: Qualitative Analysis of a Double-Blind Randomized Control Trial. *J Med Food*. 2022 Dec 1;25(12):1095–101. doi:10.1089/jmf.2022.0042
86. Scaffaro R, Lopresti F, Botta L, Rigogliuso S, Ghersi G. Integration of PCL and PLA in a monolithic porous scaffold for interface tissue engineering. *J Mech Behav Biomed Mater*. 2016 Oct;63:303–13. doi:10.1016/j.jmbbm.2016.06.021
87. Subramony SD, Dargis BR, Castillo M, Azeloglu EU, Tracey MS, Su A, et al. The guidance of stem cell differentiation by substrate alignment and mechanical stimulation. *Biomaterials*. 2013 Mar;34(8):1942–53. doi:10.1016/j.biomaterials.2012.11.012
88. Gögele C, Hoffmann C, Konrad J, Merkel R, Schwarz S, Tohidnezhad M, et al. Cyclically stretched ACL fibroblasts emigrating from spheroids adapt their cytoskeleton and ligament-related expression profile. *Cell Tissue Res*. 2021 Jun;384(3):675–90. doi:10.1007/s00441-021-03416-9

89. Bayer ML, Schjerling P, Herchenhan A, Zeltz C, Heinemeier KM, Christensen L, et al. Release of Tensile Strain on Engineered Human Tendon Tissue Disturbs Cell Adhesions, Changes Matrix Architecture, and Induces an Inflammatory Phenotype. Egles C, editor. PLoS ONE. 2014 Jan 21;9(1):e86078. doi:10.1371/journal.pone.0086078
90. Wang X, Wang D, Zhang K, Du C, Shi H. Study on the use of 3D printed guides in the individualized reconstruction of the anterior cruciate ligament [Internet]. In Review; 2023 [cited 2026 Mar 16]. Available from: <https://www.researchsquare.com/article/rs-2742921/v1> doi:10.21203/rs.3.rs-2742921/v1
91. Rankin I, Rehman H, Frame M. 3D-Printed Patient-Specific ACL Femoral Tunnel Guide from MRI. *Open Orthop J*. 2018 Feb 28;12(1):59–68. doi:10.2174/1874325001812010059
92. Abebe ES, Kim JP, Utturkar GM, Taylor DC, Spritzer CE, Moorman CT, et al. The effect of femoral tunnel placement on ACL graft orientation and length during in vivo knee flexion. *J Biomech*. 2011 Jul;44(10):1914–20. doi:10.1016/j.jbiomech.2011.04.030
93. Spalazzi JP, Dagher E, Doty SB, Guo XE, Rodeo SA, Lu HH. In Vivo Evaluation of a Tri-Phasic Composite Scaffold for Anterior Cruciate Ligament-to-Bone Integration. In: 2006 International Conference of the IEEE Engineering in Medicine and Biology Society [Internet]. New York, NY: IEEE; 2006 [cited 2026 Mar 16]. p. 525–8. Available from: <http://ieeexplore.ieee.org/document/4461802/> doi:10.1109/IEMBS.2006.259296
94. Shi Q, Chen Y, Xu Y, Chen C, Lu H. Engineering a functional ACL reconstruction graft containing a triphasic enthesis-like structure in bone tunnel for the enhancement of graft-to-bone integration. *J Orthop Transl*. 2024 Mar;45:155–67. doi:10.1016/j.jot.2024.01.004
95. Zhang B, Huang J, Narayan RJ. Gradient scaffolds for osteochondral tissue engineering and regeneration. *J Mater Chem B*. 2020;8(36):8149–70. doi:10.1039/D0TB00688B
96. Kim W, Kwon DR, Lee H, Lee J, Moon YS, Lee SC, et al. 3D bioprinted multi-layered cell constructs with gradient core-shell interface for tendon-to-bone tissue regeneration. *Bioact Mater*. 2025 Jan;43:471–90. doi:10.1016/j.bioactmat.2024.10.002
97. Youn J, Choi JH, Lee S, Lee SW, Moon BK, Song JE, et al. Pluronic F-127/Silk Fibroin for Enhanced Mechanical Property and Sustained Release Drug for Tissue Engineering Biomaterial. *Materials*. 2021 Mar 8;14(5):1287. doi:10.3390/ma14051287
98. Turnbull G, Clarke J, Picard F, Zhang W, Riches P, Li B, et al. 3D biofabrication for soft tissue and cartilage engineering. *Med Eng Phys*. 2020 Aug 1;82(1):13–39. doi:10.1016/j.medengphy.2020.06.003

99. Jafarkhani M, School of Chemical Engineering, College of Engineering, University of Tehran, Iran, Salehi Z, School of Chemical Engineering, College of Engineering, University of Tehran, Iran, Aidun A, Tissues and Biomaterials Research Group (TBRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran, et al. Bioprinting in Vascularization Strategies. *Iran Biomed J.* 2019 Jan 1;23(1):9–20. doi:10.29252/ibj.23.1.9
100. Tischer T, Aryee S, Wexel G, Steinhauser E, Adamczyk C, Eichhorn S, et al. Tissue Engineering of the Anterior Cruciate Ligament—Sodium Dodecyl Sulfate-Acellularized and Revitalized Tendons Are Inferior to Native Tendons. *Tissue Eng Part A.* 2010 Mar;16(3):1031–40. doi:10.1089/ten.tea.2009.0043
101. Weems AC, Pérez-Madrigal MM, Arno MC, Dove AP. 3D Printing for the Clinic: Examining Contemporary Polymeric Biomaterials and Their Clinical Utility. *Biomacromolecules.* 2020 Mar 9;21(3):1037–59. doi:10.1021/acs.biomac.9b01539
102. Liu A, Xue G huai, Sun M, Shao H feng, Ma C yuan, Gao Q, et al. 3D Printing Surgical Implants at the clinic: A Experimental Study on Anterior Cruciate Ligament Reconstruction. *Sci Rep.* 2016 Feb 15;6(1):21704. doi:10.1038/srep21704
103. Murray MM, Fleming BC. Biology of anterior cruciate ligament injury and repair: Kappa delta ann doner vaughn award paper 2013. *J Orthop Res.* 2013 Oct;31(10):1501–6. doi:10.1002/jor.22420
104. Russell RP, Apostolakis J, Hirose T, Cote MP, Mazzocca AD. Variability of Platelet-rich Plasma Preparations. *Sports Med Arthrosc Rev.* 2013 Dec;21(4):186–90. doi:10.1097/JSA.0000000000000007